Here, we describe a juvenile mouse model of chronic DOX-induced cardiac dysfunction. DOX treatment was initiated at 2 wk of age and continued for a period of 5 wk (25 mg/kg cumulative dose).
Researchers from Children's Hospital of Philadelphia (CHOP) have tested a preclinical model for an experimental gene therapy designed to treat multiple sulfatase deficiency (MSD), a disorder that ...
Inmagene LLC presented preclinical data for the novel noncovalent reversible Bruton tyrosine kinase (BTK) inhibitor IMG-004, which is in phase I development for autoimmune diseases.